In this sense, it has been shown that thiazolidinediones (TZDs) are neuroprotective in mutant huntingtin (mHtt) expressing cells and reduce mHtt aggregates in the brain11, 12, 13, thus supporting the concept that PPARγ may be a valid target for the management of HD. Here, PPARG is linked to Huntington disease.